Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2006

View Archived Issues

Dasatinib effective in imatinib-resistant leukemia

In vitro and in vivo characteristics of ofatumumab described

Oncolytic agents benefit from PPARgamma receptor-dependent and -independent dual mechanism

LC16m8 protects monkeys from monkeypox

Pooled data suggest heptavalent DTPw-HBV/Hib-MenAC vaccine is safe

Sosei and Mundipharma sign agreement for AD-923

ELI-154 completes second pilot phase I study

Phase II trial planned for atiprimod in advanced carcinoid cancer

Updated clinical data on tocilizumab as a treatment for arthritic disease

Phase II data report lack of efficacy for apratastat in RA

No safety concerns in phase II BPH study of NX-1207

Gantacurium chloride completes phase II study in endotracheal intubation

NVA-237 successfully completes phase IIb study in COPD

Mirtazapine results in obstructive sleep apnea do not warrant further studies

ASF-1075 studied for hand dermatitis in new study

XL-880 advances into phase II for papillary renal cell carcinoma

CMX-001 for treatment of smallpox infection cleared to begin phase I

Panzem awarded orphan drug designation for glioblastoma multiforme

NIAID to conduct antimicrobial evaluation of Viprovex

CoTherix inlicenses rights to oral and inhaled formulations of fasudil

Daytrana now available

VR-004 improves erectile performance with rapid onset of action

Revlimid approved for use in multiple myeloma

Novel antiinfective agents reported in recent patent literature

First launch for Acomplia

New agents for treating endocrine-related disorders patented

Melanocortin receptor agonist shows therapeutic potential in experimental arthritis

Phase II trial results of belimumab in systemic lupus erythematosus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...